Business Wire

Adva Network Security Layer 2 encryption technology achieves German BSI approval

2.2.2023 11:00:00 EET | Business Wire | Press release

Share

Adva Network Security today announced that its flagship 10Gbit/s edge solution with ConnectGuard Ethernet encryption has been approved for the transmission of classified data by the German Federal Office for Information Security (BSI). With BSI clearance to transport VS-NfD and NATO RESTRICTED (NR) information, the FSP 150-XG118Pro (CSH) enables customers to deploy a secure network access device guaranteed to meet stringent regulatory requirements. With comprehensive demarcation capabilities and an optional server blade, the device offers several additional advantages, such as precise synchronization and NFV hosting. Its approval by the BSI will be a major boost for customers with high security standards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005865/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BSI approval for Adva Network Security’s 10G Ethernet device will prove key for data protection at the network edge. (Photo: Business Wire)

“We work with public authorities, critical infrastructure operators and enterprises whose networks are particularly threatened by cyberattacks as they often contain the most sensitive and mission-critical data. Today’s announcement will be big news for them. Now it’s possible to securely harness a 10Gbit/s edge solution with a unique set of capabilities such as next-generation timing delivery, network virtualization and comprehensive service assurance,” said Michael Roth, GM of Adva Network Security. “We were the first in the industry to attain BSI clearance for our Layer 1 technology. Now it’s the turn of our Layer 2 solution. As a qualification, BSI approval is one of the most challenging in the industry. Achieving it not only highlights the power of the protection offered by our device, but also our commitment to security in all our business processes.”

The FSP 150-XG118Pro (CSH) is a compact, power-efficient solution for network access that combines 10Gbit/s Carrier Ethernet, IP service demarcation, and aggregation with a rich set of programmability and synchronization features. It offers robust network protection with dynamic key exchange and hardware tamper protection for the most sensitive data, and is also ready to support quantum-safe key exchange. The approval of the FSP 150-XG118Pro (CSH) by the BSI follows certification for the ADVA FSP 3000 Layer 1 encryption solution, which is already playing a key role in the transport of EU- and NATO-classified data. Customers can now have complete peace of mind that their data at both Layers 1 and 2 is secured to the most rigorous standards and compliance requirements.

“Public authorities and critical infrastructure use wide area networks and are looking to apply end-to-end encryption to standard MEF services that meet the strictest industry standards. Now our FSP 150-XG118Pro (CSH) offers a solution that ensures BSI-approved security for metro networks along with the key capabilities needed to deliver tomorrow’s services,” commented Uli Schlegel, senior director of product line management at Adva Network Security. “Our FSP 150-XG118Pro (CSH) meets tight constraints for latency, power and size. It includes a rich set of operational features and supports a pluggable server module for hosting virtualized network functions. With BSI approval, it’s the ultimate choice for rapid innovation and security at the network edge.”

Further information on the FSP 150-XG118Pro (CSH) is available in this video: https://youtu.be/6w7Z3CLBRFE.

About Adva Network Security
Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuardTM security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye